Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Prescient Therapeutics, Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Kasr El Aini Hospital
Institute of Hematology & Blood Diseases Hospital, China
Soligenix
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
M.D. Anderson Cancer Center
Kyowa Kirin Co., Ltd.
Columbia University
SciTech Development, Inc.
City of Hope Medical Center
Soligenix
University of Alabama at Birmingham
Icahn School of Medicine at Mount Sinai
Barbara Ann Karmanos Cancer Institute
Stanford University
AHS Cancer Control Alberta
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
Bristol-Myers Squibb
Thomas Jefferson University
Thomas Jefferson University
University College, London
4SC AG
Emory University
University of Pittsburgh
Indiana University
Northwestern University
European Organisation for Research and Treatment of Cancer - EORTC
Stanford University
Stanford University
National Institutes of Health Clinical Center (CC)
European Organisation for Research and Treatment of Cancer - EORTC